Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511778 · ClinicalTrials.gov registry record · Phase 4
sTErnAl heMostasiS Trial
A Phase 4 study of Excessive Bleeding During Surgery, sponsored by WakeMed Health and Hospitals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06511778 is a Phase 4 study of Excessive Bleeding During Surgery that is actively recruiting participants, run by WakeMed Health and Hospitals. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06511778, a Phase 4 study of Excessive Bleeding During Surgery, is actively recruiting participants, sponsored by WakeMed Health and Hospitals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Sternal bleeding remains an unsolved problem for cardiac surgery teams costing operative time, blood loss, and distraction from the critical operative field. As such, the following is an investigator-initiated trial to determine whether application of a topical hemostatic agent reduces sternal bleeding during cardiac surgery using sternotomy approach.
Conditions Studied
Interventions
- DRUG Hemoblast Bellows application
Study Locations (1)
North Carolina
- WakeMed Health and Hospitals - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06511778
The ClinicalTrials.gov registry entry for NCT06511778 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WakeMed Health and Hospitals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Excessive Bleeding During Surgery appearing as the primary indexed condition, and to 1 intervention - of which Hemoblast Bellows application is the first listed.
NCT06511778 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06511778 about?
NCT06511778 is a clinical study titled "sTErnAl heMostasiS Trial". Sternal bleeding remains an unsolved problem for cardiac surgery teams costing operative time, blood loss, and distraction from the critical operative field. As such, the following is an investigator-initiated trial to determine whether application of a topical hemostatic agent reduces sternal bleed...
What is the current status of trial NCT06511778?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-10-17. Estimated completion is 2026-09.
What conditions does trial NCT06511778 study?
This clinical trial studies the following conditions: Excessive Bleeding During Surgery.
What interventions are being tested in trial NCT06511778?
The interventions under investigation include: Hemoblast Bellows application (DRUG).
Who is sponsoring clinical trial NCT06511778?
This trial is sponsored by WakeMed Health and Hospitals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06511778 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.